Technical Advantage
High repeatability efficiency
By precisely controlling the protein folding pathway during the refolding process, the yield of active proteins can reach over 20%.
High activity yield
By precisely controlling the protein folding pathway during the refolding process, the yield of active proteins can reach over 40%.
Low cost production
The Escherichia coli expression system has low cost and high yield, and combined with efficient refolding technology, the overall production cost is significantly reduced.
Wide applicability
Suitable for various recombinant proteins, including enzymes, cytokines, antibody fragments, and fusion proteins.
Can scale up production
The replication process has been validated from laboratory to pilot scale and can be directly used for commercial production.
Patent protection
Having multiple invention patents related to inclusion body refolding, forming a core technological barrier.
Technical Principles
When E. coli expresses recombinant proteins, the target protein often exists in the form of inactive inclusion bodies. UKFold technology guides proteins to correctly fold and restore their natural conformation and biological activity by optimizing key parameters such as denaturation dissolution conditions, refolding buffer system composition, redox potential, temperature, and pH.
The platform integrates a high-throughput refolding condition screening system, which can quickly determine the optimal refolding conditions; Combining online monitoring technology to achieve precise control and amplification of the replication process, ensuring consistency between batches.
Application Achievements
UKFold technology has been successfully applied in the development of multiple recombinant protein drugs, including long-acting GLP-1 receptor agonists, insulin analogs, and cytokines.
This technology reduces the production cost of recombinant protein drugs by more than 50%, significantly improving the market competitiveness and patient accessibility of the product.